ERBB2 and breast cancer: With regard to BC biological profile, 183 (85.1%) tumors in 2019 and 142 (83.1%) in 2020 showed positive ER status, 138 (75.8%) and 122 (74.9%) positive PR status, 70 (38.5%) and 70 (42.9%) presented MIB1 ≥ 20%, while 34 (18.7%) and 27 (16.6%) tumors exhibited overexpressed HER2.